Tags

Type your tag names separated by a space and hit enter

[Bone targeting agents: bisphosphonates].
Bull Cancer. 2013 Nov; 100(11):1199-206.BC

Abstract

Malignant tumor osteolysis is a frequent complication in many cancers. It can cause skeletal-related events with alteration of quality of life and survival. Bisphosphonates play an important role in the management of this malignant osteolysis, via an inhibition of osteoclast-mediated bone resorption, and a potential direct antitumor activity. Their use constitutes an important therapeutic advance in patients with bone metastases so as to reduce or delay the appearance of these skeletal events. They are also useful for the treatment of hypercalcemia, which could arise in these patients. Their interest as adjuvant therapy before the onset of bone metastases is currently being evaluated.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Debiais F
Université de Poitiers, CHU de Poitiers, service de rhumatologie, 2, rue de la Milétrie, 86021 Poitiers, France.

MeSH

Bone Density Conservation AgentsBone NeoplasmsBone ResorptionBreast NeoplasmsDiphosphonatesFemaleHumansHypercalcemiaMaleOsteolysisOsteoporosisProstatic Neoplasms

Pub Type(s)

English Abstract
Journal Article
Review

Language

fre

PubMed ID

24158668

Citation

Debiais, Françoise. "[Bone Targeting Agents: Bisphosphonates]." Bulletin Du Cancer, vol. 100, no. 11, 2013, pp. 1199-206.
Debiais F. [Bone targeting agents: bisphosphonates]. Bull Cancer. 2013;100(11):1199-206.
Debiais, F. (2013). [Bone targeting agents: bisphosphonates]. Bulletin Du Cancer, 100(11), 1199-206. https://doi.org/10.1684/bdc.2013.1840
Debiais F. [Bone Targeting Agents: Bisphosphonates]. Bull Cancer. 2013;100(11):1199-206. PubMed PMID: 24158668.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Bone targeting agents: bisphosphonates]. A1 - Debiais,Françoise, PY - 2013/10/26/entrez PY - 2013/10/26/pubmed PY - 2014/1/22/medline KW - bisphosphonates KW - bone metastases KW - malignant osteolysis SP - 1199 EP - 206 JF - Bulletin du cancer JO - Bull Cancer VL - 100 IS - 11 N2 - Malignant tumor osteolysis is a frequent complication in many cancers. It can cause skeletal-related events with alteration of quality of life and survival. Bisphosphonates play an important role in the management of this malignant osteolysis, via an inhibition of osteoclast-mediated bone resorption, and a potential direct antitumor activity. Their use constitutes an important therapeutic advance in patients with bone metastases so as to reduce or delay the appearance of these skeletal events. They are also useful for the treatment of hypercalcemia, which could arise in these patients. Their interest as adjuvant therapy before the onset of bone metastases is currently being evaluated. SN - 1769-6917 UR - https://www.unboundmedicine.com/medline/citation/24158668/[Bone_targeting_agents:_bisphosphonates]_ DB - PRIME DP - Unbound Medicine ER -